PT996460E - Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6 - Google Patents

Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6

Info

Publication number
PT996460E
PT996460E PT98939278T PT98939278T PT996460E PT 996460 E PT996460 E PT 996460E PT 98939278 T PT98939278 T PT 98939278T PT 98939278 T PT98939278 T PT 98939278T PT 996460 E PT996460 E PT 996460E
Authority
PT
Portugal
Prior art keywords
beta
treatment
antibodies against
renal fibrosis
against integrin
Prior art date
Application number
PT98939278T
Other languages
English (en)
Inventor
Huang Xiaozhu
Sheppard Dean
Pytela Robert
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT996460E publication Critical patent/PT996460E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
PT98939278T 1997-08-08 1998-08-07 Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6 PT996460E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
PT996460E true PT996460E (pt) 2005-04-29

Family

ID=21995323

Family Applications (3)

Application Number Title Priority Date Filing Date
PT08004714T PT1930022E (pt) 1997-08-08 1998-08-07 Tratamento da fibrose vesical com anticorpos contra integrina alfa-v-beta 6
PT04022921T PT1504764E (pt) 1997-08-08 1998-08-07 Tratamento da fibrose hepática com anticorpos contra integrina alfa-v-beta 6
PT98939278T PT996460E (pt) 1997-08-08 1998-08-07 Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT08004714T PT1930022E (pt) 1997-08-08 1998-08-07 Tratamento da fibrose vesical com anticorpos contra integrina alfa-v-beta 6
PT04022921T PT1504764E (pt) 1997-08-08 1998-08-07 Tratamento da fibrose hepática com anticorpos contra integrina alfa-v-beta 6

Country Status (23)

Country Link
US (5) US20020004482A1 (pt)
EP (3) EP1930022B1 (pt)
JP (2) JP2001513333A (pt)
KR (1) KR100586202B1 (pt)
CN (1) CN1267224A (pt)
AT (3) ATE410179T1 (pt)
AU (1) AU739283B2 (pt)
BR (1) BR9814040A (pt)
CA (1) CA2297736A1 (pt)
CY (2) CY1110462T1 (pt)
CZ (1) CZ299768B6 (pt)
DE (2) DE69828614T2 (pt)
DK (2) DK1504764T3 (pt)
EE (1) EE04752B1 (pt)
ES (3) ES2235350T3 (pt)
HU (1) HU228900B1 (pt)
IL (2) IL134288A0 (pt)
NZ (2) NZ515955A (pt)
PL (2) PL199014B1 (pt)
PT (3) PT1930022E (pt)
RU (1) RU2221589C2 (pt)
TR (2) TR200000374T2 (pt)
WO (1) WO1999007405A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
DE69828614T2 (de) * 1997-08-08 2006-02-09 The Regents Of The University Of California, Oakland Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
CN1332714C (zh) * 1999-04-22 2007-08-22 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物组合物中的用途
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
WO2002088307A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
WO2003100033A2 (en) * 2002-03-13 2003-12-04 Biogen Idec Ma Inc. ANTI-αvβ6 ANTIBODIES
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
PT1734996E (pt) * 2004-04-02 2013-07-18 Univ California Métodos e composição para tratamento e prevenção de doenças associadas a integrina αvβ5
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
BRPI0714381A2 (pt) 2006-07-10 2013-03-05 Biogen Idec Inc composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4
ES2746925T3 (es) * 2006-08-03 2020-03-09 Medimmune Ltd Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos
JP2010506944A (ja) * 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
CN102481347A (zh) 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
NZ598464A (en) * 2009-08-21 2014-07-25 Gilead Biologics Inc Methods and compositions for treatment of pulmonary fibrotic disorders
KR20130008021A (ko) * 2010-02-04 2013-01-21 길리아드 바이오로직스, 인크. 리실 산화효소-유사 2 (ｌｏｘｌ2)에 결합하는 항체, 및 그를 위한 사용 방법
AU2013221585B2 (en) 2012-02-17 2017-03-30 Seagen Inc. Antibodies to integrin alphavbeta6 and use of same to treat cancer
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
KR20200044066A (ko) 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
US11827709B2 (en) 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
JPH04503951A (ja) 1988-12-20 1992-07-16 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション 創傷治癒に活性のあるポリペプチド―ポリマー複合体
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
PT719859E (pt) * 1994-12-20 2003-11-28 Merck Patent Gmbh Anticorpo monoclonal anti-alfa v-integrina
DE69828614T2 (de) * 1997-08-08 2006-02-09 The Regents Of The University Of California, Oakland Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6

Also Published As

Publication number Publication date
ATE410179T1 (de) 2008-10-15
US20020004482A1 (en) 2002-01-10
NZ515955A (en) 2003-04-29
CA2297736A1 (en) 1999-02-18
US20010056076A1 (en) 2001-12-27
DE69840113D1 (de) 2008-11-20
CZ2000413A3 (cs) 2000-11-15
HUP0003547A3 (en) 2002-05-28
PL199014B1 (pl) 2008-08-29
US20070148173A1 (en) 2007-06-28
KR20010022740A (ko) 2001-03-26
JP2009001587A (ja) 2009-01-08
HUP0003547A2 (hu) 2001-02-28
ATE511850T1 (de) 2011-06-15
IL134288A0 (en) 2001-04-30
ES2235350T3 (es) 2005-07-01
PT1930022E (pt) 2011-08-01
EP0996460A4 (en) 2001-03-07
PL201716B1 (pl) 2009-05-29
EP1930022B1 (en) 2011-06-08
EP0996460A1 (en) 2000-05-03
PT1504764E (pt) 2009-01-14
EP0996460B1 (en) 2005-01-12
WO1999007405A1 (en) 1999-02-18
DE69828614D1 (de) 2005-02-17
JP2001513333A (ja) 2001-09-04
DE69828614T2 (de) 2006-02-09
US20040208878A1 (en) 2004-10-21
EE200000068A (et) 2000-10-16
EP1504764B1 (en) 2008-10-08
EP1930022A1 (en) 2008-06-11
AU8774398A (en) 1999-03-01
ES2364703T3 (es) 2011-09-12
DK1504764T3 (da) 2008-11-17
AU739283B2 (en) 2001-10-11
TR200000374T2 (tr) 2000-09-21
TR200202323T2 (tr) 2002-12-23
RU2221589C2 (ru) 2004-01-20
HU228900B1 (en) 2013-06-28
CZ299768B6 (cs) 2008-11-19
ATE286742T1 (de) 2005-01-15
US6316601B1 (en) 2001-11-13
PL341029A1 (en) 2001-03-26
EE04752B1 (et) 2006-12-15
US7544358B2 (en) 2009-06-09
US7150871B2 (en) 2006-12-19
CY1111792T1 (el) 2015-10-07
CN1267224A (zh) 2000-09-20
NZ502546A (en) 2002-02-01
DK1930022T3 (da) 2011-07-25
BR9814040A (pt) 2000-10-03
IL134288A (en) 2008-07-08
KR100586202B1 (ko) 2006-06-07
CY1110462T1 (el) 2015-04-29
ES2311131T3 (es) 2009-02-01
EP1504764A1 (en) 2005-02-09
US6692741B2 (en) 2004-02-17

Similar Documents

Publication Publication Date Title
PT996460E (pt) Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
NZ288883A (en) Conjugates comprising coagulation factors
HK1029513A1 (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis
FI972287A (fi) Uudenlaisia polysubstituoituja DTPA-johdoksia ja niiden metallikomplekseja, kyseisiä komplekseja sisältäviä farmaseuttisia aineita, niiden käyttö diagnosoinnissa ja terapiassa sekä menetelmiä kyseisten kompleksinmuodostajien ja kompleksien valmistamiseksi ja menetelmiä kyseisten.
LV11868A (lv) Kermena svara modulatori to pielietojums diagnostika un terapija
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
IL117993A0 (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
HK1018204A1 (en) A use of selegiline in the manufacture of a medicament for preventing or treating peripheral neuropathy
FI961083A (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
NO994165D0 (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
PT1007055E (pt) Utilizacao de amifostina
DE69841573D1 (de) Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose
FI973185A (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
IS4387A (is) Nýtt skömmtunarform hýdroxókóbalamíns og notkun þess við sýaníðeitrunum
EP1013642A3 (de) Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
SE9503044D0 (sv) Antibodies for use in cancer therapy and diagnosis
RU99123884A (ru) Способ лечения параноидной шизофрении
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
EE9700021A (et) Fibriinile mõju avaldav monoklooniline antikeha kasutamiseks tromboosivastases ravis, farmatseutilised kompositsioonid ja ravimaine
MX9705920A (es) Tratamiento de neuropatia diabetica.
SI0804236T1 (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels